WM

Widya Mulyasasmita

Managing Partner at BEVC

United States

Overview 

Widya Mulyasasmita is the Co-Founder and Managing Partner at BEVC in the United States, with a strong background in venture capital and a focus on investing in BioTech companies in the San Francisco Bay Area. Notable career highlights include leading investments in companies like Triumvira Immunologics and OncoMyx Therapeutics at various stages, showcasing expertise in strategic decision-making and successful portfolio management.

Work Experience 

  • Co-Founder, Managing Partner

    2023 - Current

    Venture Capital firm investing in early stage companies at the intersection of science, engineering, and computation. www.bevc.com

  • Advisory Board Member

    2024

  • Adjunct Lecturer, Bioengineering

    2023

  • Founding Advisor

    2020

    Democratizing single cell biotechnology. Team is hiring! www.partillion.com

Partillion Bioscience is an early-stage life science company developing a functional single-cell analysis platform.

Raised $6,067,053.00 from +ND Capital, Vertical Venture Partners and Paladin Capital Group.

  • Board of Directors

    2022 - 2023

Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.

Raised $100,000,000.00 from Myeloma Investment Fund, Multiple Myeloma Research Foundation, Northpond Ventures, Leaps by Bayer, B Capital, ATEM Capital Fund LP, Northpond Ventures, Bloom Burton & Co., Centre for Commercialization of Cancer Immunotherapy and Leaps by Bayer.

  • Investor and Board Observer

    2022 - 2023

The company manufactures and sells the aprevo™ digital-to-device 3-D printed implant system for lumbar spine surgery.

Raised $96,985,000.00 from U.S. Venture Partners and B Capital.

  • Sr. Principal, Healthcare

    2021 - 2023

B Capital Group is a venture capital firm that backs global entrepreneurs in the field of information technology.

  • Investor and Board Observer

    2021 - 2023

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.

Raised $210,000,000.00 from Pavilion Capital, Revelation Partners, SR One, LSP BioVentures, Monashee Investment Management, B Capital, Atlas Venture, Sofinnova Partners, CaaS Capital Management and Pivotal bioVenture Partners.

  • Board of Directors

    2021 - 2023

OncoMyx Therapeutics develops oncolytic immunotherapies to assist in creating an immune response and treat cancer.

Raised $50,000,000.00 from Delos Capital, Madison Partners, Xeraya Capital, City Hill Ventures, Boehringer Ingelheim Venture Fund, Lumira Ventures, B Capital, Korea Investment Partners and LYZZ Capital.

  • Vice President

    2020 - 2021

    Red Tree VC invests in early stage companies developing therapeutics addressing significant unmet needs in oncology, neurology, and immunology. Investor & Board Observer at: Acrigen Bioscience, Excellergy, Magnus Medical, Virsti Therapeutics

Articles About Widya

Relevant Websites